Lixte Biotechnology (LIXT) Competitors $4.47 -0.15 (-3.25%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$4.55 +0.08 (+1.81%) As of 09/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. DTIL, KPTI, SLGL, IZTC, VRCA, ALXO, BCTX, ICCC, ATNM, and IMAShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Precision BioSciences (DTIL), Karyopharm Therapeutics (KPTI), Sol-Gel Technologies (SLGL), Invizyne Technologies (IZTC), Verrica Pharmaceuticals (VRCA), ALX Oncology (ALXO), Briacell Therap (BCTX), ImmuCell (ICCC), Actinium Pharmaceuticals (ATNM), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors Precision BioSciences Karyopharm Therapeutics Sol-Gel Technologies Invizyne Technologies Verrica Pharmaceuticals ALX Oncology Briacell Therap ImmuCell Actinium Pharmaceuticals ImageneBio Lixte Biotechnology (NASDAQ:LIXT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability. Does the media favor LIXT or DTIL? In the previous week, Lixte Biotechnology had 3 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Lixte Biotechnology and 0 mentions for Precision BioSciences. Lixte Biotechnology's average media sentiment score of 0.33 beat Precision BioSciences' score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Lixte Biotechnology Neutral Precision BioSciences Neutral Which has more risk & volatility, LIXT or DTIL? Lixte Biotechnology has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Do institutionals and insiders believe in LIXT or DTIL? 5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 14.8% of Lixte Biotechnology shares are held by company insiders. Comparatively, 4.5% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is LIXT or DTIL more profitable? Lixte Biotechnology has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Lixte Biotechnology's return on equity of 0.00% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Lixte BiotechnologyN/A N/A -222.90% Precision BioSciences -6,205.79%-176.47%-69.05% Which has better earnings & valuation, LIXT or DTIL? Precision BioSciences has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLixte BiotechnologyN/AN/A-$3.59M-$1.29-3.47Precision BioSciences$68.70M0.86$7.17M-$8.81-0.57 Do analysts rate LIXT or DTIL? Precision BioSciences has a consensus target price of $47.00, suggesting a potential upside of 834.39%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPrecision BioSciences beats Lixte Biotechnology on 9 of the 15 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.07M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-3.4720.8975.7526.43Price / SalesN/A458.96547.78119.09Price / CashN/A44.5237.0558.92Price / Book-3.769.9311.156.06Net Income-$3.59M-$53.38M$3.29B$266.28M7 Day Performance0.45%0.63%0.20%-0.32%1 Month Performance2.05%6.31%6.30%3.44%1 Year Performance118.05%11.63%54.81%23.11% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.779 of 5 stars$4.47-3.2%N/A+132.8%$21.07MN/A-3.474Short Interest ↓Gap UpDTILPrecision BioSciences3.9428 of 5 stars$5.04-1.8%$47.00+832.5%-49.2%$59.41M$1.26M-0.57200KPTIKaryopharm Therapeutics3.9234 of 5 stars$6.74+6.7%$34.00+404.8%-37.0%$58.70M$145.24M-0.46380News CoverageSLGLSol-Gel Technologies1.4382 of 5 stars$20.88-0.6%N/A+307.3%$58.26M$11.54M-16.9850News CoverageShort Interest ↓Gap UpIZTCInvizyne TechnologiesN/A$9.31flatN/AN/A$58.21MN/A0.0029News CoverageVRCAVerrica Pharmaceuticals4.2325 of 5 stars$6.07+1.3%$80.00+1,218.0%-77.6%$57.36M$7.57M-0.7340ALXOALX Oncology4.1675 of 5 stars$1.06-4.1%$3.30+212.8%-47.6%$57.25MN/A-0.4940News CoverageShort Interest ↓BCTXBriacell Therap3.1462 of 5 stars$8.22-89.0%$320.00+3,795.3%-92.9%$56.01MN/A-0.998Gap DownHigh Trading VolumeICCCImmuCell0.6367 of 5 stars$6.19+1.6%N/A+71.1%$55.97M$26.49M32.5570Gap UpATNMActinium Pharmaceuticals1.7484 of 5 stars$1.79-0.3%$4.50+152.1%-6.1%$55.69MN/A-1.2830Short Interest ↑IMAImageneBio2.9238 of 5 stars$13.79-2.5%$35.50+157.4%-57.8%$55.44M$9.16M-1.7970News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies DTIL Alternatives KPTI Alternatives SLGL Alternatives IZTC Alternatives VRCA Alternatives ALXO Alternatives BCTX Alternatives ICCC Alternatives ATNM Alternatives IMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIXT Stock Alerts